secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2023-12-01T23:59:59+00:00
Accession:  0001831283-23-000129
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LianBio confirms unsolicited $4.30/share buyout proposal from Concentra plus CVR
--------------------------------------------------------------------------------

- Proposal: $4.30 per share cash plus a contingent value right for 80% of net proceeds from licensing or disposition of LianBio's programs.
- Concentra Biosciences (controlled by Tang Capital Partners) made the offer; Tang Capital currently holds ~8.6% of LianBio.
- Proposal requires LianBio to have at least $515 million in cash and cash equivalents at closing, net of liabilities and costs.
- Board is reviewing the unsolicited non-binding proposal in the best interests of shareholders; further announcement expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000129/0001831283-23-000129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000129/lian-20231130.htm
  HTML page:      https://secwatch.observer/filing/0001831283-23-000129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer